Evidence map›Paper›PMID 29796183›Full record

ArticleOncotarget2018

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.

Caroline Spasojevic, Elisabetta Marangoni, Sophie Vacher, Franck Assayag, Didier Meseure, Sophie Château-Joubert, Martine Humbert, Manale Karam, Jean Marc Ricort, Christian Auclair and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Hypermethylation ofEXCLI journal · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Caroline SpasojevicPharmacogenomics Unit, Department of Genetics, Institut Curie, Paris, France.
Elisabetta MarangoniTranslational Research Department, Institut Curie, PSL Research University, Paris, France.
Sophie VacherPharmacogenomics Unit, Department of Genetics, Institut Curie, Paris, France.
Franck AssayagTranslational Research Department, Institut Curie, PSL Research University, Paris, France.
Didier MeseureDepartment of Pathology, Institut Curie, Paris, France.
Sophie Château-JoubertBioPôle Alfort, Ecole Nationale Vétérinaire d'Alfort, Maisons Alfort, France.
Martine HumbertAB Science SA, Paris, France.
Manale KaramLBPA, CNRS UMR8113, ENS Paris-Saclay, Paris-Saclay University, Cachan, France.
Jean Marc RicortLBPA, CNRS UMR8113, ENS Paris-Saclay, Paris-Saclay University, Cachan, France.
Christian AuclairAB Science SA, Paris, France.
Marie RegairazLBPA, CNRS UMR8113, ENS Paris-Saclay, Paris-Saclay University, Cachan, France.
Ivan BièchePharmacogenomics Unit, Department of Genetics, Institut Curie, Paris, France.
Institut Curie · FRAB Science (France) · FRCentre National de la Recherche Scientifique · FRÉcole Nationale Vétérinaire d'Alfort · FRQatar Foundation · QAUniversité Paris-Saclay · FRUniversité Paris Sciences et Lettres · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein Kinase D1 (PKD1) is a serine/threonine kinase encoded by the

Indexed as

PKCPKDprotein kinase D1triple-negative breast cancer

Identifiers

PMID29796183
PMCPMC5955414
OpenAlexW2801371035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.